Dataset opportunity
Pixee Medical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Pixee Medical, usable for Diagnostic AI and Computer Vision.
Score
72.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in medical imaging market = USD 1.8 billion in 2025, CAGR 35.11% (2026-2033); Global AI in diagnostics market = USD 1.97 billion in 2025, CAGR 21.74% (2026-2033).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
Medtronic seeks clearance for Hugo surgical robot in more indications
medtechdive.com ↗ - 📰press2026-06-02
Petal Surgical adds more funding for incisionless surgical robot
therobotreport.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Pixee Medical holds a highly valuable Medical Imaging Dataset (of Image modality), enriched by API, event streams, industrial data, IoT data, and medical records. This comprehensive collection of real-world patient data is exceptionally well-suited for training and validating Diagnostic AI models, enabling them to accurately identify patterns, make predictions, and offer precise diagnoses.
The business value of such data is significant, with the global AI in medical imaging market estimated at USD 1.8 billion in 2025 and projected to reach USD 20.2 billion by 2033, growing at a 35.11% CAGR from 2026 to 2033. Similarly, the AI in diagnostics market was valued at USD 1.97 billion in 2025 and is expected to grow to USD 9.68 billion by 2033, with a 21.74% CAGR from 2026 to 2033. Despite strict GDPR and data privacy regulations requiring anonymization and aggregation, the high demand for quality training data for AI development makes this dataset exceptionally valuable for advancing healthcare. ⚠ Diligence (valuable data, access to negotiate): Strict GDPR and medical data privacy regulations apply.; Data ownership of raw patient data resides with healthcare providers/patients.; Data access likely requires anonymization and aggregation. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Pixee Medical holds a highly proprietary dataset generated from over 10,000 real-world surgical procedures performed across more than 20 countries, making it exceptionally rare and valuable. This rich collection includes clinical imaging alongside unique time-series operational data captured during smartglass-assisted orthopedic surgeries. Such comprehensive, multimodal data is precisely what medical-AI and diagnostic-imaging companies require to train and validate advanced diagnostic AI and surgical guidance solutions. As the global AI in medical imaging and diagnostics markets surge, this dataset offers a critical, proven foundation for innovation and competitive advantage.
See dimension details ↓- Dataset Specificity100
dominant 'medical_records', sector healthcare, 4 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity94
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
The demand for medical imaging datasets for Diagnostic AI is exceptionally high, driven by the AI in medical imaging market's projected growth from USD 1.79 billion in 2025 to USD 26.23 billion by 2034, at a robust CAGR of 34.8%.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
5 evidence types, 5 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 3 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ review — Pixee Medical's core business is selling augmented reality software solutions that provide surgical intelligence and guidance, which falls under the exclusion criteria of selling intelligence/AI software as a product. Issues: The company's core business is selling AI software (augmented reality navigation solutions) that provides intelligence and guidance for orthopedic surgery, dire
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This evidence confirms the collection of real-time sensor data from surgical instruments and smartglasses, providing precise anatomical landmark positioning crucial for surgical navigation AI.
Medical records / imaging
This directly evidences a substantial collection of clinical imaging data from over 10,000 surgical procedures, demonstrating extensive real-world application and impact across 20+ countries, essential for training diagnostic AI.
Event streams
This highlights the capture of real-time operational data from smartglasses during orthopedic surgeries, detailing instrument positioning and surgeon interaction for enhanced procedural efficiency.
Industrial data
This indicates the availability of surgical parameter data combined with augmented reality visualizations, offering insights into the operational environment of smartglass-guided procedures and augmented reality integration.
API access
This confirms the capability for secure, multimodal data exchange with third-party web solutions, indicating a well-structured and accessible data architecture for interoperable datasets.
Coverage
Scanned sources
Deliverable
Premium dataset report
Pixee Medical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = USD 1.8 billion in 2025, CAGR 35.11% (2026-2033); Global AI in diagnostics market = USD 1.97 billion in 2025, CAGR 21.74% (2026-2033).. Investment score 72.9/100 (confidence 0.63). Recommended action: Data Sharing Agreement.